Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses AOEs in the ponatinib phase II PACE trial (NCT01207440) in patients with Ph+ leukemia.
Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.7550?af=R&
Advertisement